Evidence map›Paper›PMID 34884981›Full record

ArticleCancers2021

The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.

Bertrand Tombal, Arnulf Stenzl, David Cella, Yohann Loriot, Andrew J Armstrong, Karim Fizazi, Tomasz Beer, Cora N Sternberg, Maha Hussain, Cristina Ivanescu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 5 countries.

Bertrand TombalCliniques Universitaires Saint Luc, Avenue Hippocrate, 10, B-1200 Bruxelles, Belgium.
Arnulf StenzlDepartment of Urology, Eberhard Karls University of Tübingen, Hoppe-Seyler-Straße 3, 72076 Tübingen, Germany.ORCID 0000-0003-4207-9928
David CellaFeinberg School of Medicine, Northwestern University, 633 Clark Street, Evanston, IL 60208, USA.
Yohann LoriotInstitut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif CEDEX, 94805 Paris, France.
Andrew J ArmstrongDuke Cancer Institute Center for Prostate & Urologic Cancers, Duke University, 905 La Salle Street, GSRB1 Room 3006, Durham, NC 27710, USA.
Karim FizaziInstitut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif CEDEX, 94805 Paris, France.
Tomasz BeerOregon Health & Science University Center for Health & Healing, 3485 S. Bond Avenue, Building 2, Portland, OR 97239, USA.
Cora N SternbergDivision of Hematology and Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, Belfer Research Building, 413 East 69th Street, Room 1412, New York, NY 10021, USA.
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 303 East Superior Street, Suite 3-107, Chicago, IL 60611, USA.
Cristina IvanescuIQVIA, Diana Building, Office 314, Herikerbergweg 181, Zuidoost, 1101 CN Amsterdam, The Netherlands.
Arijit GanguliAstellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL 60062, USA.
Krishnan RamaswamyPfizer Oncology, 235 East 42nd Street, Mailstop 219/06/32, New York, NY 10017, USA.
Fred SaadUniversity of Montréal Hospital Center (CHUM), Montréal Cancer Institute, University of Montréal, Pavillon R, 900, Rue St-Denis, Porte R10-464, Montréal, QC H2X 0A9, Canada.ORCID 0000-0003-2986-5617
Institut Gustave Roussy · FRNorthwestern University · USAstellas Pharma (United States) · USCliniques Universitaires Saint-Luc · BECornell University · USDuke University · USOregon Health & Science University · USPfizer (United States) · USUniversité de Montréal · CAUniversity of Tübingen · DE

Funding

Astellas Pharma Inc. NAPfizer Inc. NA
6 · The paper itself

Abstract

This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed)

Indexed as

anti-neoplastic agentscancer painprostatic neoplasmsquality of lifetreatment outcome

Identifiers

PMID34884981
PMCPMC8657254
OpenAlexW3214853603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.